Axcan is a privately-held, leading multinational specialty pharmaceutical company focused on gastroenterology. The Company develops and markets a broad line of prescription products to treat a range of gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency. Axcan's products are marketed by its own specialized sales forces in North America and the European Union and through commercial collaborations in many markets around the world.
April 28, 2008
Axcan Provides Preliminary Revenue Results for the Second Quarter of Fiscal Year 2008
February 25, 2008
Axcan Announces Completion of Transaction With TPG Capital
February 13, 2008
Axcan and TPG Capital Receive Investment Canada Act Approval in Connection With Proposed Acquisition
Isabelle Adjahi
Senior Director, Investor Relations and Communications
Axcan Pharma Inc.
597, Laurier Blvd.
Mont-Saint-Hilaire, QC., J3H 6C4
Canada